Stay 
Trading Conditions
Products
Tools
AstraZeneca announced on Wednesday its plan to sell the rights to its migraine drug Zomig to German company Grunenthal for up to $302 million.
Upon completion, AstraZeneca is expected to receive $200 million and up to $102 million more on hitting future milestones.
The pharmaceutical company said the deal will be complete this month.
